Navigation Links
Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
Date:1/24/2008

Company Received $5.2 Million in Cost Recovery from EAP in 2007

RICHMOND, Va., Jan. 24 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, today provided an update on the IPLEX(TM) Expanded Access Program (EAP) in Italy for the treatment of Amyotrophic Lateral Sclerosis (ALS). Since early 2007, the EAP has grown to include 15 physicians and approximately 70 subjects have been enrolled into the program. Additional subjects continue to be enrolled into the program. IPLEX(TM) appears to have been safe and well tolerated in the subject population to date and no individuals have dropped out of the study for reasons related to IPLEX(TM). The Company received cost recovery of $5.2 million for drug supplies for the full-year 2007.

The study utilizes a Revised ALS Functional Rating Scale (ALSFRS) to monitor the progress of the subjects. The ALSFRS is used to determine a patient's capacity and independence in several functional activities including speech, salivation, swallowing, handwriting, cutting foods and handling utensils, dressing and hygiene, turning in bed, walking, climbing stairs, and respiratory function. The purpose of collecting this information is to help ensure safety and to gain an understanding as to whether IPLEX(TM) provides any benefit to these subjects.

ALS, often referred to as Lou Gehrig's disease, is a progressive neurodegenerative disorder that affects nerve cells in the brain and spinal cord. Motor neurons reach from the brain to the spinal cord and from the spinal cord to the muscles throughout the body. The progressive degeneration of the motor neurons in ALS eventually leads to their death. When the motor neurons die, the ability of the brain to initiate and control muscle movement is lost. With voluntary muscle movement action progressively negatively affected, those patients in the later stage of the disease may become totally paralyzed. The ALS Associati
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy
2. EpiCept Provides Update on Clinical and Regulatory Progress with Ceplene(TM) and EpiCept(TM) NP-1 Cream
3. DuPont Provides Technology for Washington Hospital Centers Emergency Department
4. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
5. ImaRx Provides Update on TUCSON Phase I/II Clinical Trial in Acute Ischemic Stroke
6. Progen Provides Update on Phase 3 Clinical Program for PI-88 in Liver Cancer
7. IDM Pharma Provides Update of Product Pipeline and Announces Plans to Evaluate Strategic Alternatives for the Company
8. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
9. Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery
10. Replidyne Provides Strategic Update
11. BioCryst Provides Forodesine HCl Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 The spinal column is one of the ... carried to and from the brain through the column control ... Injury or ailment here can be life altering, and leave ... control over their body. Though back injury and disease can ... are more options available to make things better than ever ...
(Date:8/21/2014)... N.C. , Aug. 21, 2014 /PRNewswire-iReach/ -- ... Medical Equipment, Inc. for the third straight year, ... Inc. 500|5000, an exclusive ranking of the nation,s ... comprehensive look at the most important segment of ... Pandora, Timberland, Dell, Domino,s Pizza, LinkedIn, Zillow, and ...
(Date:8/21/2014)... YORK , August 21, 2014 ... Israeli subsidiary, BreedIT Ltd., the exclusive worldwide license ... software for plant breeders and researchers, today is ... a joint venture with Seach Ltd, a leading ... formed to research and develop new breeds of ...
Breaking Medicine Technology:Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4
... SEATTLE, April 21 Dendreon Corporation (Nasdaq: ... the first patient in a Phase 1 clinical trial ... is Dendreon,s lead small molecule drug candidate designed to ... cells and induce cell death. The trial is ...
... Circassia Ltd, a specialty,biopharmaceutical company focused on allergy, ... clinical study of its ToleroMune(R) technology in,allergy patients ... II results,that demonstrated the potential clinical benefits of ... with allergy-associated,asthma. , The ...
Cached Medicine Technology:Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer 2Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer 3Circassia's Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients 2
(Date:8/22/2014)... 2014 The first ORTC Public ... Microsoft, and Google. ( http://ortc.org/wp-content/uploads/2014/08/ortc.html ) , ... to create a WebRTC 1.1 API with exceptional ... WebRTC, ORTC (Object Real-time Communication) enables plugin-free real-time ... specifically tailored to provide the direct control needed ...
(Date:8/22/2014)... 22, 2014 The Berkowitz Law Firm ... a client who suffered severe, permanent injuries in an ... driver (docket number FST-CV13-6018309-S). The case was pending in ... According to Jennifer Amdur of The Berkowitz Law Firm ... all of whom were allegedly injured following ...
(Date:8/22/2014)... FastFingerprints is adding a new location to ... Wednesday, August 27, 2014 and is located at 3740 ... the addition of this new office, that will bring ... Cleveland area. Our new Cleveland-Midtown location will provide ... hours of operation will be Monday-Friday 8:00am – 5:00pm ...
(Date:8/22/2014)... 22, 2014 Teen substance abuse has ... OH. Unfortunately, most young adults never receive the professional ... the community, the new Troubled Teens Columbus helpline was ... to overcome their drug and alcohol dependencies . ... teens and their parents can speak directly to a ...
(Date:8/22/2014)... 2014 Dr Murray Grossan was interviewed for ... , In the October 2014 issue of Bottom Line Personal ... his method of treating snoring, and in some cases Obstructive ... half of all adults snore occasionally, and about 25% do ... air passages in the back of the throat tend to ...
Breaking Medicine News(10 mins):Health News:Hookflash, Google and Microsoft lead on ORTC / WebRTC 1.1 Public Draft 2Health News:Hookflash, Google and Microsoft lead on ORTC / WebRTC 1.1 Public Draft 3Health News:The Berkowitz Law Firm LLC Reaches a $2 Million Settlement for a Client Allegedly Injured in Drunk Driving Accident 2Health News:FastFingerprints Expands In The Cleveland Ohio Area 2Health News:FastFingerprints Expands In The Cleveland Ohio Area 3Health News:New Helpline in Columbus Assists Troubled Teen Find Youth Rehab 2Health News:Dr Murray Grossan Explains how and why Singing Exercises Stop Snoring 2Health News:Dr Murray Grossan Explains how and why Singing Exercises Stop Snoring 3
... VNDA ) ("Vanda" or the "Company") announced today ... contest by withdrawing its nominations of director candidates for election ... liquidate the Company. TCP had previously notified the Company of ... of its candidates to the Vanda Board at the Company,s ...
... is National Lupus Awareness MonthWASHINGTON, May 7 ... risks associated with breast cancer and heart disease, but ... aware of another potentially fatal disease that disproportionately strikes ... The disease is lupus.Although more than 1.5 million ...
... May 7 /PRNewswire-Asia-FirstCall/ -- China Pharma,Holdings, Inc. ("China Pharma") ... pharmaceutical products in China, today,announced that it plans to ... 2009, before the market opens. , ... 8:00 am ET on May 15, 2009 to,discuss fiscal ...
... (NYSE: MTD ) today announced the webcast of its ... Conference in New York on Thursday, May 14, 2009, at 10:40 ... presentation, visit the investor relations page on the Company,s Web site ... /investors . A replay of the webcast will be ...
... Recent scientific studies published in the medical journals ... Journal of Nutrition, and others, showed that the ... anti-cancer activities. Gene-Eden is a dietary supplement ... unique, patent-pending formulation. Gene-Eden was introduced in February ...
... Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on ... results for the three month period ended March 31, 2009. ... in the first quarter of 2008. The net loss for ... diluted share, compared to a net loss of $762,000, or ...
Cached Medicine News:Health News:Vanda Pharmaceuticals Announces Withdrawal of Director Nominees and Proposal to Liquidate Submitted by Tang Capital 2Health News:Public Lacks Awareness of Serious Disease With Life-Threatening Complications 2Health News:Public Lacks Awareness of Serious Disease With Life-Threatening Complications 3Health News:China Pharma Holdings, Inc. to Report First Quarter 2009 Financial Results on May 15, 2009 2Health News:The Center for the Biology of Chronic Disease Highlights Anti-Cancer Activities of the Food Extracts Quercetin, EGCG, Glycyrrhizin, and Trans-Cinnamaldehyde 2Health News:PLC Systems Reports First Quarter 2009 Results 2Health News:PLC Systems Reports First Quarter 2009 Results 3Health News:PLC Systems Reports First Quarter 2009 Results 4Health News:PLC Systems Reports First Quarter 2009 Results 5
Standard Deflectable Catheters...
The Explorer ST "soft tip" catheter has a proximal shaft with a soft tip. It is available in both a 5F and 6F shaft configuration....
... offers a wide range of deflectable curve ... needs of children and other patients with ... demanding specifications using only the finest materials. ... wire braiding and extrusion technologies results in ...
A-Focus I & II Catheters. A-Focus steerable atrial mapping catheter. Available in 10, 12, 14 and 20 electrode configurations. (Shown with 14 electrodes)....
Medicine Products: